Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

VX-880 (formerly known as STx-02) derives from Vertex’ near $1 billion acquisition of Semma in 2019, and has started enrolling patients in a phase 1/2 study in the US. The therapy takes the form ...

KING OF PRUSSIA, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA. The event will ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.45% to $495.42 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.49% to ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 7.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Vertex, Inc. (NASDAQ: VERX) has announced plans to host an Investor Day on Wednesday, March 19, in Philadelphia, PA. This ...

Vertex Pharmaceuticals EVP Ourania Tatsis sold 3,242 shares worth $1.62 million under a pre-arranged plan. The sale, executed on March 10, 2025, priced each share at $499.99, with Tatsis still holding ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.